BayerC, ShiK, AstnerST, MafteiCA, and VaupelP. Acute versus chronic hypoxia: why a simplified classification is simply not enough. Int J Radiat Oncol Biol Phys, 80: 965–968, 2011.
2.
HöckelM, SchlengerK, HöckelS, AralB, SchäfferU, and VaupelP. Tumor hypoxia in pelvic recurrences of cervical cancer. Int J Cancer, 79: 365–369, 1998.
3.
HöckelM and VaupelP. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst, 93: 266–276, 2001.
4.
IakovlevVV, PintilieM, MorrisonA, FylesAW, HillRP, and HedleyDW. Effect of distributional heterogeneity on the analysis of tumor hypoxia based on carbonic anhydrase IX. Lab Invest, 87: 1206–1217, 2007.
5.
JanssenHL, HaustermansKM, SprongD, BlommestijnG, HoflandI, HoebersFJ, BlijweertE, RaleighJA, SemenzaGL, VariaMA, BalmAJ, van VelthuysenML, DelaereP, SciotR, and BeggAC. HIF-1α, pimonidazole, and iododeoxyuridine to estimate hypoxia and perfusion in human head-and-neck tumors. Int J Radiat Oncol Biol Phys, 54: 1537–1549, 2002.
6.
MayerA, HöckelM, and VaupelP. Carbonic anhydrase IX expression and tumor oxygenation status do not correlate at the microregional level in locally advanced cancers of the uterine cervix. Clin Cancer Res, 11: 7220–7225, 2005.
7.
MayerA, HöckelM, and VaupelP. Endogenous hypoxia markers in locally advanced cancers of the uterine cervix: reality or wishful thinking?. Strahlenther Onkol, 182: 501–510, 2006.
8.
MayerA, HöckelM, WreeA, and VaupelP. Microregional expression of glucose transporter-1 and oxygenation status: lack of correlation in locally advanced cervical cancers. Clin Cancer Res, 11: 2768–2773, 2005.
9.
MayerA, WreeA, HöckelM, LeoC, PilchH, and VaupelP. Lack of correlation between expression of HIF-1α protein and oxygenation status in identical tissue areas of squamous cell carcinomas of the uterine cervix. Cancer Res, 64: 5876–5881, 2004.
10.
ThewsO, KelleherDK, and VaupelPW. pO2-mapping of experimental rat tumors: visualization and statistical analysis. In: Tumor Oxygenation,edited by VaupelPW, KelleherDK, GünderothM. Stuttgart, Jena, NY: Gustav Fischer Verlag, 1995, pp. 27–38.
11.
ThewsO and VaupelP. Relevant parameters for describing the oxygenation status of solid tumors. Strahlenther Onkol, 172: 239–243, 1996.
12.
ThomlinsonRH and GrayLH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer, 9: 539–549, 1955.
13.
VaupelP. The role of hypoxia-induced factors in tumor progression. Oncologist, 9 (Suppl 5): 10–17, 2004.
14.
VaupelP. Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist, 13 (Suppl 3): 21–26, 2008.
15.
VaupelP. Prognostic potential of the pre-therapeutic tumor oxygenation status. Adv Exp Med Biol, 645: 241–246, 2009.
16.
VaupelP, HöckelM, and MayerA. Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal, 9: 1221–1235, 2007.
17.
VaupelP and MayerA. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev, 26: 225–239, 2007.
18.
VaupelP and MayerA. Hypoxia in tumors: pathogenesis-related classification, characterization of hypoxia subtypes, and associated biological and clinical implications. Adv Exp Med Biol, 812: 19–24, 2014.
19.
VaupelP, MayerA, and HöckelM. Tumor hypoxia and malignant progression. Methods Enzymol, 381: 335–354, 2004.
20.
WalshJC, LebedevA, AtenE, MadsenK, MarcianoL, and KolbHC. The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities. Antioxid Redox Signal, 21: 1516–1554, 2014.
